• Why Attend?
  • Speakers
  • Contact Us

Why Attend?

​​From logistics and order-to-cash to market access and global expansion, launch teams must navigate a growing number of operational and regulatory requirements.

Explore how Cencora brings together logistics, distribution, order-to-cash management, title model solutions, and market-entry consulting to create an integrated launch approach.

Discover how an integrated model enables companies to launch efficiently, reduce operational burden, and maintain ownership of their commercialization strategy as they expand globally.​ 

Learning Objectives of this webinar:

  • ​​Learn how integrated logistics can reduce complexity and improve execution across global markets​
  • ​​Discover how end-to-end order-to-cash services reduces the administrative burden placed on internal launch teams and alleviates the pressure to scale up international teams​
  • ​​Understand how title model solutions provide manufacturers with greater flexibility and support market entry, improve cash-flow efficiency, and preserve ownership​
  • ​​Identify the key operational and regulatory challenges that launch teams face when scaling globally.​

Speakers

Select a speaker to learn more

Back
​​Gert Jan Van Der Hulst​
​​Vice President, Integrated Solutions and Commercialization​, Cencora

GertJan (GJ) brings 25+ years commercial experience across clinical development and commercialisation. He has broad experience across clinical development and market access with leading CROs like ICON, PAREXEL and PPD. In his current role VP Integrated Solutions & Commercialisation he leverages Cencora’s foundations to bring integrated outsourced commercial services to emerging biotechs in Europe and/or the US.

Next speaker
Back
Krystal Haynes
​​Senior Director, International 3PL Business Development, Cencora

​​Krystal Haynes serves as the Senior Director of International 3PL Business Development for ICS – part of the Cencora family of companies. In her role, Krystal is responsible for the strategic and operational oversight of the ICS business development team, supporting manufacturers for their commercial launch, including innovative cell and gene therapies.​

Next speaker

Enquiry